ERBB2 and colorectal cancer: Encorafenib plus cetuximab therapy for BRAF V600E–mutated, pertuzumab plus trastuzumab therapy for ERBB2-amplified, and pembrolizumab monotherapy, nivolumab monotherapy, and nivolumab plus ipilimumab therapy for MSI-high tumors have been shown to be effective and approved by the FDA for advanced colorectal cancer.6,8,41,42 The frequency of TMB-high was also comparable between the advanced anal and rectal AD groups.